A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor)
combined with apatinib and capecitabine as first-line therapy in patients with advanced
hepatocellular carcinoma.